Immunic (IMUX) Net Income towards Common Stockholders (2013 - 2026)

Immunic has disclosed Net Income towards Common Stockholders across 14 years of filings, most recently posting -$32.5 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$32.5 million, down 21.89% year-over-year; the trailing twelve-month figure through Mar 2026 was -$108.0 million (down 9.54% YoY), and the FY2025 annual result was -$102.2 million, down 7.95% from the prior year.
• Net Income towards Common Stockholders came in at -$32.5 million for Q1 2026 at Immunic, down from -$23.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$19.9 million in Q3 2022 to a low of -$56.6 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$24.1 million (2023), against an average of -$26.1 million.
• Across the five-year window, Net Income towards Common Stockholders sank 160.89% in 2022 and soared 59.67% in 2023, its largest moves.
• Immunic's Net Income towards Common Stockholders stood at -$56.6 million in 2022, then jumped by 59.67% to -$22.8 million in 2023, then decreased by 10.34% to -$25.2 million in 2024, then increased by 8.22% to -$23.1 million in 2025, then slumped by 40.4% to -$32.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$32.5 million (Q1 2026), -$23.1 million (Q4 2025), and -$25.6 million (Q3 2025), per Business Quant data.